Twelves, Chris <br/><br/>
Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.  [electronic resource] 

 -  Clinical breast cancer  Apr 2010 
 - 160-3 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1938-0666 
<br/><br/><label>Standard No.: </label>10.3816/CBC.2010.n.023  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Furans--therapeutic use<br/>Humans<br/>Ketones--therapeutic use<br/>Neoplasm Recurrence, Local--drug therapy